Condition: Locally Advanced Cholangiocarcinoma · Intrahepatic Cholangiocarcinoma · Solid Tumor · Sponsor: Tyra Biosciences, Inc
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
This description comes directly from the study's public registry record.
Grace Indyk · (619)728-4805 · TyraClinicalTrials@tyra.bio
Always discuss trial participation with your own doctor first.
| University of California San Francisco (UCSF) | San Francisco, California, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06160752